Article
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
Journal of gastroenterology - 1 Mar 2015
Oze Tsugiko, Hiramatsu Naoki, Yakushijin Takayuki, Yamada Ryoko, Harada Naoki, Morishita Naoki, Yamada Akira, Oshita Masahide, Kaneko Akira, Suzuki Kunio, Inui Yoshiaki, Tamura Shinji, Yoshihara Harumasa, Imai Yasuharu, Miyagi Takuya, Yoshida Yuichi, Tatsumi Tomohide, Kasahara Akinori, Hayashi Norio, Takehara Tetsuo
Abstract excerpt
BACKGROUND: Triple therapy with telaprevir (TVR), pegylated interferon and ribavirin has improved antiviral efficacy in patients with chronic hepatitis C (CH-C). However, the severe adverse effects caused by TVR are important to resolve. In this prospective, randomized, multicenter, open-label study, the antiviral efficacy and safety in the reduced administration of TVR were examined. METHODS: A total of 81 CH-C...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.